Method 1 was removed from the most-recently cleared version of endotool iv.Monarch has notified all customers whose parameters include the use of method 1 of this issue, reminding them to always have the basal transition dosing recommendation verified by a physician prior to administering the dose.A tip card has also been provided with this information.To eliminate the risk of this issue recurring, monarch is requesting that customers upgrade to the newest software version of the endotool iv (b)(4) application, which only uses method 0 to calculate tdd.Customers who cannot upgrade soon will be offered a parameter adjustment, switching from use of method 1 to method 0 in their application.
|
Monarch medical technologies has received complaints from customers that the basal transition dosing recommendation calculated by endotool iv 1.8.0 - 1.10.1 applications was higher than expected.None of the reported cases resulted in patient harm, as the bedside clinician was able to easily recognize the dose as being too high.Investigation concluded that one of the methods used for the tdd (total daily dose) calculation can result in an elevated basal transition dosing recommendation.The reporting customers each had "method 1" in use when they received elevated basal transition dosing recommendations from the application.Due to recurrence of this incident, we initiated an internal review of cases and found that the tdd method 1 was the cause of high transition recommendation in the prior cases, resulting in monarch the filing a 30 day mdr for this issue.This has been corrected in the next version of the software.Customers have been instructed to select a different tdd method in the affected versions of the software until they are able to upgrade to the new version.
|